---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-060726"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2026-05-14T12:06:12+00:00"
generated_at: "2026-05-14T12:18:20.221738+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M

## Summary
- Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.
- Cash and cash equivalents were $71.5M at March 31, 2026; subsequent $100M equity offering and $25M upfront payment to J&J for bota-vec.
- Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; positive 3-year data from Phase 1 AQUAx study.
- Appointed Penny Fleck as Chief Development Officer; Stuart Naylor as Chief Scientific Officer, Ophthalmology.
- Reacquired full rights to bota-vec for XLRP from J&J with $25M upfront plus milestones and mid-teens royalties.

## SEC filing metadata
- accession: 0001104659-26-060726
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2026-05-14T12:06:12+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/0001104659-26-060726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/mgtx-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-060726
- JSON: https://secwatch.observer/filing/0001104659-26-060726.json
- Plain text: https://secwatch.observer/filing/0001104659-26-060726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.